Suppr超能文献

国际 382 例狼疮肾炎患儿队列研究 - 24 个月时的表现、治疗和结局。

International cohort of 382 children with lupus nephritis - presentation, treatment and outcome at 24 months.

机构信息

Paediatric Unit, Maggiore Hospital, Azienda USL, Bologna, Italy.

Pediatric Nephrology, Department of Pediatrics, Baylor College of Medicine, Texas Children's Hospital, Houston, TX, USA.

出版信息

Pediatr Nephrol. 2023 Nov;38(11):3699-3709. doi: 10.1007/s00467-023-06018-5. Epub 2023 May 24.

Abstract

BACKGROUND

Children with lupus have a higher chance of nephritis and worse kidney outcome than adult patients.

METHODS

We retrospectively analyzed clinical presentation, treatment and 24-month kidney outcome in a cohort of 382 patients (≤ 18 years old) with lupus nephritis (LN) class ≥ III diagnosed and treated in the last 10 years in 23 international centers.

RESULTS

The mean age at onset was 11 years 9 months and 72.8% were females. Fifty-seven percent and 34% achieved complete and partial remission at 24-month follow-up, respectively. Patients with LN class III achieved complete remission more often than those with classes IV or V (mixed and pure). Only 89 of 351 patients maintained stable complete kidney remission from the 6 to 24 months of follow-up. eGFR ≥ 90 ml/min/1.73 m at diagnosis and biopsy class III were predictive of stable kidney remission. The youngest and the oldest age quartiles (2y-9y, 5m) (14y, 2m-18y,2m) showed lower rates of stable remission (17% and 20.7%, respectively) compared to the two other age groups (29.9% and 33.7%), while there was no difference in gender. No difference in achieving stable remission was found between children who received mycophenolate or cyclophosphamide as induction treatment.

CONCLUSION

Our data show that the rate of complete remission in patients with LN is still not high enough. Severe kidney involvement at diagnosis was the most important risk factor for not achieving stable remission while different induction treatments did not impact outcome. Randomized treatment trials involving children and adolescents with LN are needed to improve outcome for these children. A higher resolution version of the Graphical abstract is available as Supplementary information.

摘要

背景

儿童狼疮患者发生肾炎和肾脏不良结局的风险高于成人患者。

方法

我们回顾性分析了过去 10 年在 23 个国际中心诊断和治疗的 382 例(≤18 岁)狼疮肾炎(LN)≥III 级的患儿的临床表现、治疗方法和 24 个月的肾脏结局。

结果

发病时的平均年龄为 11 岁 9 个月,72.8%为女性。分别有 57%和 34%的患者在 24 个月随访时达到完全缓解和部分缓解。LN Ⅲ级患者的完全缓解率高于Ⅳ级或Ⅴ级(混合性和纯合性)患者。在 351 例患者中,仅有 89 例从 6 个月到 24 个月的随访期间保持稳定的完全肾脏缓解。诊断时 eGFR≥90ml/min/1.73m2 和活检为Ⅲ级是稳定肾脏缓解的预测因素。年龄最小和最大四分位数(2y-9y,5m)(14y,2m-18y,2m)与其他两个年龄组(29.9%和 33.7%)相比,稳定缓解率较低(分别为 17%和 20.7%),而性别之间没有差异。接受吗替麦考酚酯或环磷酰胺作为诱导治疗的儿童在达到稳定缓解方面没有差异。

结论

我们的数据显示,LN 患者完全缓解的比例仍然不够高。诊断时严重的肾脏受累是未达到稳定缓解的最重要危险因素,而不同的诱导治疗对结果没有影响。需要对儿童和青少年 LN 进行随机治疗试验,以改善这些儿童的结局。更高分辨率的图表摘要可在补充信息中获得。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验